Ta. D'Amico et al., A biologic risk model for stage I lung cancer: Immunohistochemical analysis of 408 patients with the use of ten molecular markers, J THOR SURG, 117(4), 1999, pp. 736-742
Citations number
27
Categorie Soggetti
Cardiovascular & Respiratory Systems","Cardiovascular & Hematology Research
Objective: The standard treatment of patients with stage I non-small cell l
ung cancer is resection of the primary tumor; however, the recurrence rate
is 28% to 45%. This study evaluates a panel of molecular markers in a large
population of patients with stage I non-small cell lung cancer to determin
e the prognostic value of each marker and to create a biologic risk model.
Methods: Pathologic specimens were collected From 408 consecutive patients
after complete resection for stage I non-small cell lung cancer at a single
institution, with follow-up of at least 5 years, A panel of 10 molecular m
arkers was chosen for immunohistochemical analysis of the primary tumor on
the basis of differing oncogenic mechanisms. Local tumor expansion requires
growth regulating proteins (epidermal growth factor receptor, the protoonc
ogene erb-b2); apoptosis proteins (p53, bcl-2); and cell cycle regulating p
roteins (retinoblastoma recessive oncogene, KI-67), Local tumor invasion re
quires angiogenesis (factor viii), The development of distant metastases in
volves the expression of adhesion proteins (CD-44, sialyl-Tn, blood group A
). Cox proportional hazards regression analysis was used to construct an in
dependent risk model for cancer recurrence and death. Results: Multivariabl
e analysis demonstrated significantly elevated risk for the following molec
ular markers: p53 (hazard ratio, 1.68; P = .004); factor viii (hazard ratio
, 1.47; P = .033); erb-b2 (hazard ratio, 1.43; P = .044); CD-44 (hazard rat
io, 1.40; P = .050); and retinoblastoma recessive oncogene (hazard ratio, 0
.747; P = .084), Conclusions: Five molecular markers were associated with t
he risk of recurrence and death, representing independent metastatic pathwa
ys: apoptosis (p53), angiogenesis (factor viii), growth regulation (erb-b2)
, adhesion (CD-44), and cell cycle regulation (retinoblastoma recessive onc
ogene), This study demonstrates the validity of this molecular biologic ris
k model in patients with stage I nonsmall cell lung cancer.